Table 5.
Prevalence of HIV drug resistance among adults initiating and reinitiating ART in Uruguay by regimen prescribed, 2018–2019.
| NNRTI-Based ART Prescribed | DTG-Based ART Prescribed |
ATV/r- or LPV/r-Based ART Prescribed |
||||
|---|---|---|---|---|---|---|
| n/N | %, 95% CI | n/N | %, 95% CI | n/N | %, 95% CI | |
| NRTI | ||||||
| Any | 10/113 | 8.8, 8.0–9.7 | 9/59 | 15.0, 13.7–16.4 | 2/24 | 8.9, 5.6–13.9 |
| ABC | 4/113 | 3.5, 3.1–3.9 | 6/59 | 10.1, 8.9–11.4 | 2/24 | 8.9, 5.6–13.9 |
| 3TC or FTC | 1/113 | 0.9, 0.7–1.1 | 3/59 | 5.0, 4.2–6.0 | 0/24 | 0.0, 0.0–13.8 |
| TDF | 2/113 | 1.7, 1.5–2.0 | 3/59 | 5.0, 4.2–6.0 | 2/24 | 8.9, 5.6–13.9 |
| ZDV | 7/113 | 6.2, 5.5–7.1 | 7/59 | 11.7, 10.5–12.9 | 2/24 | 8.9, 5.6–13.9 |
| NNRTI | ||||||
| EFV or NVP | 18/113 | 15.9, 14.4–17.5 | 9/59 | 15.0, 13.7–16.3 | 3/24 | 13.3, 9.2–18.8 |
| DOR | 3/113 | 2.6, 2.4–2.8 | 7/59 | 11.6, 10.6–12.7 | 1/24 | 4.4, 2.4–8.1 |
| EFV | 17/113 | 15.0, 13.6–16.6 | 9/59 | 15.0, 13.7–16.3 | 3/24 | 13.3, 9.2–18.8 |
| ETR | 3/113 | 2.5, 2.5–2.6 | 7/59 | 11.6, 10.6–12.7 | 1/24 | 4.1, 3.3–5.1 |
| NVP | 18/113 | 15.9, 14.4–17.5 | 9/59 | 15.0, 13.7–16.3 | 3/24 | 13.3, 9.2–18.8 |
| RPV | 15/113 | 13.5, 11.6–15.7 | 9/59 | 15.0, 13.7–16.3 | 3/24 | 13.0, 9.4–17.7 |
| PI/r | ||||||
| ATV/r, DRV/r or LPV/r | 1/113 | 0.8, 0.8–0.9 | 1/59 | 1.6, 1.6–1.7 | 1/24 | 4.8, 2.0–10.9 |
| ATV/r | 1/113 | 0.8, 0.8–0.9 | 1/59 | 1.6, 1.6–1.7 | 1/24 | 4.8, 2.0–10.9 |
| DRV/r | 0/113 | 0.0, 0.0–3.3 | 0/59 | 0.0, 0.0–6.1 | 1/24 | 4.8, 2.0–10.9 |
| LPV/r | 1/113 | 0.8, 0.8–0.9 | 1/59 | 1.6, 1.6–1.7 | 1/24 | 4.8, 2.0–10.9 |
| INSTI | ||||||
| Any | 17/113 | 15.1, 13.4–16.9 | 7/60 | 11.7, 10.3–13.2 | 1/24 | 4.0, 3.7–4.3 |
| BIC | 0/113 | 0.0, 0.0–3.3 | 0/60 | 0.0, 0.0–6.0 | 0/24 | 0.0, 0.0–13.8 |
| CAB | 0/113 | 0.0, 0.0–3.3 | 0/60 | 0.0, 0.0–6.0 | 0/24 | 0.0, 0.0–13.8 |
| DTG | 0/113 | 0.0, 0.0–3.3 | 0/60 | 0.0, 0.0–6.0 | 0/24 | 0.0, 0.0–13.8 |
| EVG | 17/113 | 15.1, 13.4–16.9 | 7/60 | 11.7, 10.3–13.2 | 1/24 | 4.0, 3.7–4.3 |
| RAL | 17/113 | 15.1, 13.4–16.9 | 7/60 | 11.7, 10.3–13.2 | 1/24 | 4.0, 3.7–4.3 |
Study design-weighted proportion and 95% confidence interval. HIV drug resistance was defined as the presence of a penalty score ≥15 using the Stanford HIVdb algorithm. ABC: abacavir; ART: antiretroviral therapy; ATV/r: atazanavir/ritonavir; BIC: bictegravir; CAB: cabotegravir; CI: confidence interval; DOR: doravirine; DRV/r: darunavir/ritonavir; DTG: dolutegravir; EFV: efavirenz; ETR: etravirine; EVG: elvitegravir; FTC: emtricitabine; INSTI: integrase strand-transfer inhibitor; LPV/r: lopinavir/ritonavir; NNRTI: non-nucleoside reverse-transcriptase inhibitor; NRTI: nucleoside reverse-transcriptase inhibitor; NVP: nevirapine; PI/r: boosted protease inhibitor; RAL: raltegravir; RPV: rilpivirine; TDF: tenofovir disoproxil fumarate; ZDV: zidovudine; 3TC: lamivudine.